




Perspectives in Percutaneous Penetration

Volume 9a



Edited by KR Brain and KA Walters

Abstracts of presentations at the Ninth International Perspectives in Percutaneous Penetration Conference held in La Grande Motte April 2004

Acknowledgements

The organisers are grateful to all of the organisations who have supported the Ninth Perspectives in Percutaneous Penetration Conference.

An-eX
Bioskin
EU
Macrochem
Mylan Technologies
Omnipharm Research
Syngenta CTL
Transpharma
Unilever Research

Scientific Advisory Board

J Bouwstra, Leiden, The Netherlands
R Bronaugh, Washington, USA
W Dressler, Stamford, USA
D Esdaile, Sophia Antipolis, France
K Feld, Kings Mills, USA
G Flynn, Ann Arbor, USA
J Heylings, Alderley Park, UK
N Kitson, Vancouver, Canada
H Maibach, San Francisco, USA
W Meuling, Zeist, The Netherlands
M Ponec, Leiden, The Netherlands
M Roberts, Brisbane, Australia
A Watkinson, Galashiels, UK
A Williams, Bradford, UK
F Williams, Newcastle, UK

INFLUENCE OF THE VEHICLE ON CETIRIZINE PERMEATION	23
C CIURLIZZA, E ESCRIBANO, J LAUROBA, A BOIX AND AC CALPENA	
INVERSION OF THE LIPIDS OF THE OUTER MONOLAYER OF THE LIPOSOMES AS STRATEGY OF ADAPTATION TO ENVIRONMENTS OF DIFFERENT POLARITY	24
O LÓPEZ, M CÓCERA, P. GONZÁLEZ AND A DE LA MAZA	
CHOLESTEROL/CHOLESTEROL SULFATE RATIO IN STRATUM CORNEUM MODELS: COULD IT BE AN INDICATOR FOR ASSESSING PATHOLOGICAL SKIN?	25
M CÓCERA, O LÓPEZ, C LÓPEZ-IGLESIAS AND A DE LA MAZA	
EFFECT OF IONIC STRENGTH ON THE <i>EX-VIVO</i> IONTOPHORETIC TRANSDERMAL DIFFUSION OF SUMATRIPTAN.....	26
A FEMENÍA-FONT, V MERINO, V RODILLA AND A LÓPEZ-CASTELLANO	
OLEIC ACID ENHANCES SKIN PENETRATION OF SUMATRIPTAN	27
A FEMENÍA-FONT, C BALAGUER, JE MESONERO, V MERINO, V RODILLA AND A LÓPEZ-CASTELLANO	
EFFECT OF TERPENE PRETREATMENT ON THE <i>EX-VIVO</i> TRANSDERMAL PERMEATION OF SUMATRIPTAN	28
A FEMENÍA-FONT, V MERINO, V RODILLA AND A LÓPEZ-CASTELLANO	
INFLUENCE OF FOUR SKIN CARE FORMULATIONS ON THE SKIN BARRIER FUNCTION IN VITRO.....	29
C RIBAUD-LECLERC, M-P VERDIER, J SIP, J LECLAIRE AND F BENECH	
DELIVERY RATE MODIFICATION USING NON-OCCLUSIVE METERED-DOSE TRANSDERMAL SPRAY FORMULATIONS	30
NF WILKINS, TM MORGAN AND BC FINNIN	
TRANSDERMAL DELIVERY USING ULTRASOUND: ELUCIDATING THE MECHANISM INVOLVED	31
I LAVON, N GROSSMAN AND J KOST	
IN VITRO SKIN ACCUMULATION OF NICOTINAMIDE AFTER TOPICAL APPLICATION	32
S NICOLI, V D'ACCHIOLI, M GUARRACINO AND P SANTI	
THIOLCHICOSIDE CONCENTRATION IN THE STRATUM CORNEUM AFTER APPLICATION OF A DERMAL PATCH.....	33
A RAZZINI, C PADULA, P COLOMBO, S NICOLI AND P SANTI	
NON-VIRAL GENE DELIVERY TO EPIDERMAL KERATINOCYTES.....	34
SA COULMAN, C ALLENDER, D BARROW, C GATELEY, A ANSTEY AND JC BIRCHALL	
MICROFABRICATED MICRONEEDLES CHANNELS PROVIDE "PATHWAYS" FOR THE SUSTAINED RELEASE OF PLASMID DNA FROM CARBOPOL-940 HYDROGELS	35
M PEARTON, C GATELEY, A ANSTEY, CJ ALLENDER, KR BRAIN AND JC BIRCHALL	
PERMEATION AND DISTRIBUTION OF QUININE AND QUINIDINE AFTER APPLICATION TO PDMS AND HEAT-SEPARATED HUMAN EPIDERMAL MEMBRANES IN DIFFERENT VEHICLES	36
S COURTOIS, CM HEARD AND KR BRAIN	
EFFECT OF VEHICLE SOLUBILITY PARAMETER ON PERMEATION AND DISTRIBUTION OF NAPROXEN AND PRODRUGS	37
G STODDART, CM HEARD AND KR BRAIN	
RELATIONSHIP BETWEEN SOLUBILITY PARAMETER AND UPTAKE AND METABOLISM OF NAPROXEN ESTER PRODRUGS APPLIED AS THIN FILMS	38
G STODDART, CM HEARD AND KR BRAIN	
RATIONALISATION OF ENZYMIC HYDROLYSIS OF DERMAL ESTER PRODRUGS USING AN ACTIVE SITE MODEL.....	39
A MORRIS, KR BRAIN, CM HEARD, G MCNAUGHTON AND G STODDART	
A NOVEL APPLICATION OF THE FRANZ DIFFUSION CELL: PRELIMINARY ASSESSMENT OF BENZO[A]PYRENE PERMEATION THROUGH SILICONE MEMBRANE	40
J ZHANG, CG AZZI, CH PURDON, MI BLOCK, JM CHAPMEN AND EW SMITH	
PRELIMINARY ASSESSMENT OF THE PERMEATION OF 4-(METHYL-NITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE (NNK) THROUGH PORCINE ESOPHAGEAL TISSUE USING THE FRANZ DIFFUSION CELL	41
CG AZZI, J ZHANG, CH PURDON, MI BLOCK, JM CHAPMAN AND EW SMITH	

INVERSION OF THE LIPIDS OF THE OUTER MONOLAYER OF THE LIPOSOMES AS STRATEGY OF ADAPTATION TO ENVIRONMENTS OF DIFFERENT POLARITY

O LÓPEZ¹, M CÓCERA¹, P. GONZÁLEZ² AND A DE LA MAZA¹

¹C.I.D.-C.S.I.C. Dpt. Tensioactius, Barcelona, Spain and ²Transtechincs S.L., Barcelona, Spain

Use of liposomes in the field of dermatology and dermopharmacy has become more and more popular. From practical and theoretical viewpoints liposomes constitute suitable carriers that facilitate topical penetration¹. However, a number of questions about the mechanism of action of these vesicular structures on the skin have to be still clarified.

Liposomes are constituted of membranes similar to the lipid layers of the intercellular spaces of the stratum corneum (SC)². Their structure consists of two lipid monolayers in which the polar parts of the molecules are placed in contact with water and the apolar parts are located in the hydrophobic membrane core. Considering this arrangement, it may be predicted that variations in the polarity of the medium could lead to a spontaneous inversion of the lipid molecules of the liposome outer monolayer. In this work we studied this possible mechanism as a strategy of adaptation of the liposomes to environments of different polarity. Moreover, a method to form "a priori" this kind of vesicle, that might be called "*inverted liposomes*", was investigated. Additionally, the stability and properties of these systems were evaluated.

Liposomes constituted of phospholipids were formed in an aqueous medium³. In order to induce inversion of the lipids of the outer monolayer the polarity of the medium was gradually changed by addition of different volumes of ethanol. To measure the degree of inversion of the lipids due to changes in the polarity of the medium, the electronic paramagnetic resonance (EPR) technique was used⁴. The size, shape and lamellarity of the vesicles in the different polar media were determined by dynamic light scattering (DLS)³.


The results of the present study seemed to indicate that phospholipid liposomes show molecular mobility depending on the polarity of the medium. This molecular mobility due to the ethanol might induce spontaneous formation of liposomes in which lipids of the outer bilayer are inverted (inverted liposomes). Our results demonstrated the stability of this type of liposome in media containing < 30% ethanol.

Inverted liposomes could have a higher affinity to the less polar environments, such as the SC intercellular lipids. Moreover, these vesicles, that could cross more easily this potent barrier, might be of great interest in the development of new topical preparations.

1. B Van den Berg, JA Bouwstra, HE Junginger and PW Wertz (1999) .J Control. Rel., 62, 367-373
2. O López, M Cócera, A de la Maza, L Coderch and JL Parra (2000) Biochim. Biophys. Acta, 1508, 196-209
3. O López, A de la Maza, L Coderch, C López-Iglesias, E Wehrlí and JL Parra (1998) FEBS Letters, 426, 314-318
4. J Fonollosa, M Martí, A de la Maza, M Sabés, JL Parra and L Coderch (2000) Langmuir 16(11), 4808-4812

INDEX

- 1,8-CINEOLE, 27
¹⁰⁹CD²⁺, 57
¹³⁷CS⁺, 57
¹³⁷PM³⁺, 57
 2-BUTOXYETHANOL, 8
 3-(4-METHYLBENZYLIDEN)-CAMPOR, 46
 5-FLUOROURACIL, 17, 27, 65
⁶⁰CO²⁺, 57
 6-HYDROXYSPHINGOSINE, 1
 ABLATION, 14, 30
 ABSORPTION, 20, 52, 72, 73, 82, 84, 85, 87, 98,
 101, 102, 105
 ACICLOVIR, 38
 ACID CERAMIDASE, 56
 ACNE, 16
 ACTIVE SITE MODEL, 38
 ACYLCERAMIDES, 1
 ADAMI, 101
 AFM, 5
 AGEING, 18, 19
 AIACHE, 41
 AKOMEAH, 85
 ALBRECHT, 77
 ALCOHOL DEHYDROGENASE, 2
 ALCOHOLS, 72
 ALDOSTERONE, 62
 ALEXANDER, 52, 53
 ALGORITHM, 104
 ALLENDER, 33, 34
 ALLERGY, 106
 ALONSO, 20
 ANATOMICAL REGIONS, 47
 ANDARY, 19
 ANISSIMOV, 60
 ANSTEY, 33, 34
 ANTIBACTERIAL, 16
 ANTIFUNGAL, 54
 ANTI-INFLAMMATORY, 16
 ANTIOXIDANT, 19, 20, 77
 ATOPIC DERMATITIS, 97
 ATOPIC ECZEMA, 6
 AVOBENZONE, 61
 AZZI, 39, 40
 BALAGUER, 26
 BAP, 39
 BAROLI, 58, 59
 BARRIER FUNCTION, 28
 BARRIER INTEGRITY, 69
 BARRIER RECOVERY, 50, 70
 BARROW, 33
 BARRY, 65
 BAUEROVA, 57
 BECHGAARD, 55
 BENECH, 28
 BENFELDT, 15, 78
 BENSON, 63
 BENZENE, 73
 BENZO(A)PYRENE, 8, 39
 BENZOATE, 63, 64
 BENZOCAINE, 2
 BENZOIC ACID, 7, 64
 BENZYL ALCOHOL, 2
 BENZYDAMINE, 63
 BETAMETHASONE, 48
 BEYSSAC, 41
 BINARY SYSTEMS, 55
 BIOAVAILABILITY, 46
 BIOEQUIVALENCE, 15
 BIOEQUIVALENCE STUDIES, 78
 BIOLOGICAL MONITORING, 99
 BIOMONITORING, 8
 BIOSCAVENGER, 13
 BIRCHALL, 33, 34
 BISABOLOL, 27
 BLOCK, 39, 40
 BOIX, 22
 BOLA, 44
 BONNER, 64, 65
 BOURNER, 79
 BOUWSTRA, 90
 BRADY, 72
 BRAIN, 11, 12, 34, 35, 36, 37, 38, 44, 52, 65
 BREAKTHROUGH TIME, 12
 BRES, 19
 BRONAUGH, 2
 BROWN, 85
 BUCCAL DELIVERY, 74
 BUJNOVA, 57
 BUNGE, 86, 87, 88, 89
 BUPIVACAINE, 21
 BURACZEWSKA, 70
 BUTOXYETHANOL, 81, 83, 91, 98, 100, 104
 BUTYLPARABEN, 85
 CABRAL-LILLY, 17
 CAFFEIC ACID, 19
 CAFFEINE, 7, 8, 28, 79, 83, 85, 91, 96
 CAGE, 92
 CALKOEN, 97
 CALPENA, 21, 22
 CANCER, 19, 39, 40
 CAPTOPRIL, 52, 53
 CARBAMATE, 10, 103
 CARBOPOL, 34, 74
 CARCINOGEN, 39, 40
 CAROTENOIDS, 77
 CCD, 18
 CDS-TC-32, 17
 CERAMIDE ANALOGUES, 49
 CERAMIDES, 1, 31, 56, 71
 CETIRIZINE, 22
 CHAN, 4, 54
 CHAPMAN, 40
 CHAPMEN, 39
 CHARALAMBOPOULOU, 66, 67
 CHEMICAL BIOLOGICAL WARFARE, 12
 CHEMICAL WARFARE AGENTS, 13
 CHILCOTT, 73
 CHLOROGENIC ACID, 19
 CHOLESTEROL, 24, 71
 CHOLESTEROL SULFATE, 24
 CHOLINESTERASES, 13
 CHRISTIANSEN, 55
 CHROMIUM, 101, 102
 CIONI, 102
 CIURLIZZA, 22
 CLARKSON, 13
 CLOBETASOL PROPIONATE, 47, 48
 CMBA, 64
 COBALT, 101, 102
 CÔCERA, 23, 24
 COCKER, 91
 CODERCH, 20

- CODRUG, 17
 COLOMBO, 32
 COMPARTMENTAL MODELING, 90
 COMPONENT INTERACTIONS, 51
 CONFOCAL, 75
 CONTAMINATED SOILS, 87
 CONTAMINATION, 13, 57, 78
 CORISH, 9, 94, 95
 CORK, 6
 CORNEODESMOSIN, 6
 CORNEODESMOSOMES, 6
 CORNEOMETER, 70
 CORRELATE, 35
 CORRELATION, 2, 8, 30, 40, 45, 85, 88
 CORTICOSTERONE, 62
 COSMETIC, I
 COSMETIC OILS, 106
 CO-SOLVENT, 55
 COULMAN, 33
 COURTOIS, 35
 CRITICAL FACTORS, 7
 CROSS, 60, 61, 62
 CROW, 69
 CULTURE, 1, 33, 56, 61
 CYANOPHENOL, 87
 D'ACCHIOLI, 31
 DALTON, 72, 73
 DANHOF, 90
 DATABASE, 84
 DE LA MAZA, 23, 24 
 DE PAEPE, 56
 DECONTAMINATION, 13
 DEGLIN, 87
 DERMATO-PHARMACOKINETIC, 15, 78
 DERMATO-PHARMACOKINETIC (DPK) METHOD,
 78
 DICK, 91
 DICLOFENAC, 74, 93
 DIDRIKSEN, 55
 DIFFUSIVITY, 62, 67, 85
 DIFLUNISAL, 55
 DIMETHOATE, 103
 DIMETHYL ISOSORBIDE, 55
 DISCRIMINATION, 35
 DISEASED SKIN, 15
 DISTRIBUTION, 84, 93
 DLS, 23
 DOCTOR, 13
 DOLEZAL, 49, 50
 DOMÉNECH, 21
 DPPH, 20
 DUAL THERAPY, 17
 DUNCKELMANN, 5
 DUNN, 11, 16
 DYES, 75
 DYKES, 44
 ECONAIL™, 54
 EDETOX, I, 7, 8, 9, 10, 84, 92, 94, 95, 98, 99, 100,
 102, 103, 104, 106
 ELIAS, 56
 ENHANCER, 26, 27, 28, 29, 39, 40, 46, 49, 50, 54,
 104
 EPICATECHIN, 20
 EPIDERMAL MEMBRANES, 35
 EPR, 23
 ESCRIBANO, 21, 22
 ESTERASE, 2, 50, 53
 ESTRADIOL, 51, 65
 ESTROGEST, 51
 ETHNIC, 18
 ETHOXYETHANOL, 81
 ETIDOCAINE, 21
 EUCALYPTOL, 27
 EUCALYPTUS OIL, 106
 EVAPORATE, 88
 EVOREL, 51
 EXTRAPOLATION, 96
 FDA, 78
 FEMENIA-FONT, 25, 26, 27
 FENTANYL, 105
 FIGUEIREDO, 45, 46
 FINITE DOSE, 21, 29, 82, 96
 FINNIN, 29
 FITZPATRICK, 93, 94
 FLUFENAMIC ACID, 71, 76
 FLUORESCENCE, 19, 34, 75, 77, 99
 FLUORESCENT MICROSCOPY, 19
 FREE RADICAL, 20
 FUNGICIDES, 103
 GARCÍA ORTIZ, 78
 GATELEY, 33, 34
 GD, 13
 GENE, 6, 33, 34
 GERSHONOWITZ, 14
 GLUCANS, 57
 GLUCOSAMINE, 64
 GLUTAMIC ACID, 65
 GLYCOL ETHERS, 10, 81
 GLYPHOSATE, 11
 GOHAIN, 54
 GOLDEN, 94, 95
 GONZÁLEZ, 23
 GOODYER, 89
 GORDON, 13
 GRANDJEAN, 104
 GREAVES, 83
 GREEN, 11, 44
 GROSSMAN, 30
 GUARRACINO, 31
 GUINEA PIG, 2
 GULLICK, 52, 53
 HAIGH, 41, 42, 43
 HALOPERIDOL, 38
 HATTERSLEY, 72, 73
 HAYDEN, 61
 HD, 13
 HEARD, 35, 36, 37, 38
 HENDERSON, 6
 HOLLERAN, 56
 HONORÉ HANSEN, 78
 HOUBEN, 56
 HRABALEK, 49, 50
 HUANG, 47, 48
 HUI, 54
 HUMAN GROWTH HORMONE, 14
 HYDRATION, 12, 26, 66, 68
 HYDRATION STATE, 66
 HYDROCORTISONE, 62
 HYDROGEN-BONDING ABILITY, 49
 HYDROLYSIS, 38
 HYPER-PIGMENTED SPOTS, 18
 HYPOTHESES, 89
 IBUPROFEN, 41, 42, 43, 44, 63
 IMANIDIS, 45, 46
 IN VIVO, 29, 44, 92
 INDULONA, 57
 INGRAM, 52, 53
 INSECTICIDE, 103
 INSULIN, 14, 64
 INTEGRITY, 106

- INVERTED LIPOSOMES, 23
 ION PAIRING, 63
 IONIC STRENGTH, 25
 IONTOPHORETIC, 25, 90
 IRRITATION, 11, 70, 74, 80, 106
 ISOMERS, 35
 ISOPROPYL MYRISTATE, 50, 55, 58, 59, 71
 JACOBI, 75, 76
 JAKASA, 97, 100
 JONES, 91
 JØRGENSEN, 55
 JSLIST, 12
 KAINOURGIAKIS, 67
 KANELLOPOULOS, 66
 KASSAI, 57
 KERATINOCYTES, 1, 17, 31, 33, 34, 56, 61
 KETOCONAZOLE, 48
 KEZIC, 8, 95, 96, 97, 100
 KOPRDA, 57
 KORINTH, 98, 99, 100
 KOST, 30
 KRÜSE, 95, 96, 100
 KUSUM DEVI, 74
 LADEMANN, 75, 76, 77
 LAG TIME, 71, 82, 89, 90, 101
 LAMESCH, 71
 LARESE, 101
 LARSEN, 105
 LASER DOPPLER FLOWMETER, 70
 LASER SCANNING MICROSCOPY, 75
 LAUROBA, 22
 LAVON, 30
 LAWRENZ, 75
 LECLAIRE, 28
 LEHR, 71
 LENN, 47, 48
 LEVIN, 14
 LIDOCAINE, 21, 30, 32
 LIMONENE, 22, 27
 LIPID EXTRACTION, 71
 LIPOSOMES, 23, 24
 LOCAL ANAESTHETICS, 21
 LODEN, 70
 LÓPEZ, 23, 24
 LÓPEZ-CASTELLANO, 25, 26, 27
 LÓPEZ-IGLESIAS, 24
 LOZANO, 20
 LPD VECTOR, 33
 LYCOPENE, 77
 M291, 13
 MAAS, 98
 MACALADY, 87
 MACROMOLECULES, 14
 MADDEN, 69
 MAGNUSSON, 62
 MAIBACH, 3, 54
 MAINA, 101
 MALATHION, 82
 MANE, 74
 MANNITOL, 58, 59, 65
 MARKS, 44
 MARSIN, 41
 MARTI-MESTRES, 19
 MARTIN, 19, 85
 MASS, 83
 MATHEMATICAL MODEL, 89, 96
 MATHEMATICAL MODELLING, 68, 84, 91, 95
 MATTS, 18
 MAXIMUM FLUX, 60, 62, 83
 MCNAUGHTON, 38
 MEIERS, 71
 MENNÉ, 78
 MENTHOL, 39, 40, 44
 MERINO, 25, 26, 27
 MESONERO, 26
 METABOLISM, 2, 37, 53, 74, 100
 METALS, 10, 101, 102
 METHIOCARB, 103
 METHYL PARABEN, 85, 86
 METHYL SALICYLATE, 2
 METOPROLOL, 74
 METRONIDAZOLE, 78
 MICROCHANNELS, 14
 MICRODIALYSIS, 8, 15, 78, 84, 98, 99, 100
 MICROELECTRONIC, 14
 MICROEMULSIONS, 58, 59
 MICROFABRICATION, 33, 34
 MICRONEEDLES, 34
 MODEL MEMBRANE, 87
 MODELLING, 9, 93
 MOISTURIZING CREAM, 70
 MOLECULAR POLARITY, 65
 MOLECULAR WEIGHT, 97, 103
 MONTOMOLI, 102
 MORGAN, 29
 MORPHOLOGY, 66
 MORPHOMIC, 5
 MORRIS, 38
 MOSS, 52, 53
 MUCOADHESIVE FILMS, 74
 MURPHY, 6
 MUSTARD, 13
 N-ACETYLTRANSFERASE, 2
 NAPROXEN, 36, 37, 38
 NAZIR, 85
 NETZLAFF, 71
 NEUTRON SCATTERING, 66, 67
 NICKEL, 101, 102
 NICOLI, 31, 32
 NICOTINAMIDE, 31
 NIELLOUD, 19
 NIELSEN, 83, 103, 104, 105, 106
 NMR, 63
 NNK, 40
 NON-STEADY STATE DATA, 95
 NON-VIABLE, 2
 NOTARIO, 20
 NUGROHO, 90
 O'CONNOR, 92
 O'NEILL, 93
 OBACH, 21
 OBJECTIVE ASSESSMENT, 18
 OCCLUSION, 73
 OCTANE SULPHONATE, 63
 OCTANOL, 32, 52, 60, 62, 63, 88, 91, 94, 96, 97
 OCTINOXATE, 61
 OCTISALATE, 29
 OCTOCRYLENE, 61
 OECD, 69, 83, 92, 93
 OLEIC ACID, 26
 OLIGOMERS, 97
 OLUX, 47, 48
 ONYCHOMYCOSIS, 54
 ORAPOSIDE, 19
 ORGANOPHOSPHATE, 10, 13, 82
 OROBRANCHE, 19
 OTBERG, 75
 OXYBENZONE, 28, 61
 P-450, 2
 PACLOBUTRAZOL, 103

- PADIMATE O, 29, 61
 PADULA, 32
 PAH, 99
 PALAT, 49
 PARATHION, 82
 PARRA, 20
 PARTITION CO-EFFICIENTS, 93
 PASQUA, 90
 PATCH-NON-PATCH[®], 32
 PDMS, 35, 51, 52, 63
 PEARTON, 34
 PEASE, 79
 PEG, 97
 PELLANDA, 45, 46
 PENDLINGTON, 79
 PENETRATION ENHANCERS, 3, 4
 PEPPERMINT OIL, 106
 PERMEABILITY COEFFICIENTS, 60, 86
 PEROXIDATION, 20
 PERSONAL PROTECTION, 12
 PESTICIDES, 10, 13, 82, 92, 103
 PG CAPRYL CAPRATE, 35
 PH OF SKIN, 70, 93
 PHILLIP, 14
 PHOSPHOLIPIDS, 23
 PHYSICO-CHEMICAL PARAMETERS, 84
 PHYTOSPHINGOSINE, 1
 PIG, 19
 PILOSEBACEOUS, 18
 PINTO, 68
 PIRIMICARB, 103
 PLASMID, 33, 34
 PLASTIC OCCLUSION STRESS TEST, 68
 PMDS, 19
 POLYAROMATIC HYDROCARBONS, 10
 POLYCYCLIC AROMATIC HYDROCARBONS, 99
 POLYDIMETHYLSILOXANE, 63, 81
 POLYETHYLENE GLYCOLS, 97
 POLYPHENOLIC, 19, 20
 POLYURETHANE FOAM, 13
 PONEC, 1
 POST, 68
 POULSEN, 3
 POULSEN'S THEORY, 55
 PPD, 79
 P-PHENYLENEDIAMINE, 79
 PREDICTION, 7, 8, 35, 67, 73, 81, 84, 93, 94
 PRILOCAINE, 21
 PROCHLORAZ, 103
 PRODRUGS, 36, 37, 38, 52, 53
 PROGESTERONE, 41, 62
 PROGESTOGENS, 51
 PROPOXUR, 83, 98
 PROPYLENE GLYCOL, 22, 35, 46, 55, 64
 PSORIASIS, 17
 PSYCHOGIOS, 67
 PUGH, 51, 52, 53
 PURDON, 39, 40, 41, 42, 43, 45
 PYRENE, 8, 39, 99
 QSAR, 9, 10, 84, 91, 93, 94, 96
 QUERALT, 21
 QUINIDINE, 35
 QUININE, 35
 RADIONUCLIDE IONS, 57
 RAMAN SPECTROSCOPY, 77
 RAMÓN, 20
 RAMOS, 19
 RAPESEED OIL, 106
 RASHID, 65
 RAZZINI, 32
 RECEPTOR CHAMBER AREA, 72
 RECEPTOR CHAMBER FLUID COMPOSITION,
 72, 73
 RECONSTRUCTED EPIDERMIS, 1
 REFER, 55
 REPEAT DOSE, 79
 RESERVOIR, 62, 76, 85
 RETARDERS, 11
 RIBAUD-LECLERC, 28
 RICHTER, 5, 75
 RISK ASSESSMENT, I, 8, 10, 83, 84, 92, 104
 ROBERTS, 60, 61, 62
 ROBUST, 7, 10
 ROBUSTNESS, 7
 RODILLA, 25, 26, 27
 RODRIGUES, 68
 ROGIERS, 56
 ROMONCHUK, 86
 ROPER, 69
 ROSADO, 68
 RUDAEV, 14
 RUTTER, 72
 SACKS, 14
 SALICYLAMIDE, 55
 SALICYLANILIDES, 16
 SANDERS, 79
 SANDWICH, 65
 SANTI, 31, 32
 SARTORELLI, 102, 104
 SARVEIYA, 63
 SAUNDERS, 51, 61, 79
 SCHAEFER, 76
 SCHÄFER, 71
 SCHALLER, 100
 SCHLÜTER, 5
 SEM, 5, 80, 81, 82, 83
 SEPA, 4, 54
 SEPA[®] 0009, 54
 SHAH, 78
 SHUNT PATHWAY, 65
 SILICONE MEMBRANE, 39, 40, 42, 43
 SIMONSEN, 55
 SIP, 28
 SISINNI, 102
 SKIN – IMAGING, 18
 SKIN ABSORPTION, 2, 84, 92, 98
 SKIN BARRIER, 5, 6, 15, 24, 28, 50, 58, 68, 69, 70,
 99, 106
 SKIN CARE, 18, 28, 58, 79
 SKIN CARE FORMULATIONS, 28
 SKIN NOTATION, 104
 SKIN THICKNESS, 83
 SLS, 30, 70, 80, 97
 SMART, 52, 53
 SMITH, 39, 40, 41, 42, 43, 45, 46
 SMITH PEASE, 80
 SNAKE SKIN, 41
 SODIUM AZIDE, 64
 SODIUM LAURYL SULFATE, 30, 70, 97
 SOIL, 87
 SOLUBILITY, 13, 21, 22, 35, 51, 52, 55, 60, 62, 87,
 88, 96, 99, 103
 SOLUBILITY PARAMETER, 36, 37
 SOMAN, 13
 SONOPHORESIS, 30
 SØRENSEN, 103, 105
 SOYEI, 84
 SPHINGOSINE, 1, 56
 STEMPFER, 88
 STERIODIS, 66, 67

INVERSION OF THE LIPIDS OF THE OUTER MONOLAYER OF LIPOSOMES AS STRATEGY OF ADAPTATION TO ENVIRONMENTS OF DIFFERENT POLARITY

O LÓPEZ¹, M CÓCERA¹, P GONZÁLEZ² and A DE LA MAZA¹, ¹C.I.D.-C.S.I.C. Dpt. Tensioactivos, Barcelona, Spain and ²Transferronics S.L. Barcelona, Spain



INTRODUCTION

Liposomes are constituted by membranes similar to the lipid layers of the intercellular spaces of the stratum corneum (SC). Their structure consists in two lipid monolayers in which the polar parts of the molecules are placed in contact with water and the apolar parts are located in the hydrophobic membrane core. Considering this arrangement, it may be predicted that variations in the polarity of the medium could lead to the spontaneous inversion of the lipid molecules of the liposome outer monolayer.

The objective of this work is to study this possible mechanism as a strategy of adaptation of the liposomes to environments of different polarity. The method to form "a priori" this kind of "adapted" vesicles, that might be called "Inverted Liposomes", was investigated. Additionally, the stability and properties of these systems were evaluated.

METHODS

Liposomes constituted by phospholipids were formed by the evaporation-hydration method in an aqueous medium [1]. Once formed, the polarity of the medium was gradually changed by addition of different volumes of ethanol, obtaining final ethanol percentages of 10%, 25%, 20%, 25%, 30%, 40% and 50%. The final lipid concentration was 10mg/ml.


The size and shape of the vesicles in the different polar media were determined by dynamic light scattering (DLS) [1].

To measure the degree of inversion of the lipids due to changes in the polarity of the medium, the electronic paramagnetic resonance (EPR) technique was used [2]. The paramagnetic probe 16-doxil stearic acid was included in the lipid phase of liposomes. The τ parameter (rotational correlation time) which describes the degree of freedom of the electronic spin movement was calculated from the EPR spectra according to the following equation:

$$\tau = 6.5 \times 10^{-10} W_0 [(W_1/W_0) - 3]$$

W_0 and W_1 are the width of the lines at medium and high fields of the first derivative of each absorption spectrum [2].

Figure 1: EPR spectrum of a liposome labeled with the 16-doxil stearic acid.



RESULTS AND DISCUSSION

A. Formation and characterization of liposomes.

Figure 2: Change of size and polydispersity index of the liposomes when the proportion of ethanol in the medium is increased.

ETHANOL	DIAMETER (nm)	POLYDISPERSITY INDEX
0	130	0.010
10	120	0.080
20	180	0.050
30	300	0.130
40	400	0.578
50	500	0.899

*Phospholipid liposomes in pure aqueous solution are populations of stable and spherical vesicles with an approximate diameter of 150 nm and a polydispersity index of 0.01.


*Liposomes in media containing less than 30% ethanol were stable for at least one week.

*Ethanol percentages higher than 30% produced structural changes in the liposomes probably related with the first steps of vesicle solubilization.

Since the aim of the work is to study the inversion of the lipids of the outer bilayer without damage of the liposomes, it was considered that an ethanol proportion of 30% is the maximum acceptable to ensure the liposome integrity.

Figure 2: Effect of the medium polarity on the mobility of the lipids of the liposome outer monolayer.

Figure 2: Rotational correlation time (τ) variation when the percentage of ethanol in the medium is increased. This parameter is inversely related with the mobility of the label and therefore with the mobility of the lipids in the bilayer. Thus, the decrease of this parameter when the proportion of ethanol in the medium is increased shows an increase of the molecular mobility.



*Solutions containing 30-20% of ethanol showed a maximum molecular mobility without changes of the physicochemical parameters of the liposomes (size and shape).

*Between 20-30% ethanol, an increase of τ was observed i.e., a decrease of the mobility of the lipids that could be due to an increase in the number of inverted lipid molecules. This fact could hinder the mobility of the probe.

Thus, EPR showed that ethanol was able to induce molecular mobility in the lipids that form the liposomes. This mobility might be related with the process of inversion of the lipids that constitute the outer monolayer of the liposomes forming the "Inverted Liposomes" (scheme A). The increase in the molecular mobility might cause an increase in the flexibility of the bilayer which might induce the deformation of the liposomes (scheme B).



The inclusion of ethanol in liposome formulation is not new. Touitou et al. have described a carrier for enhanced skin delivery, the ethosomal system, which are composed of phospholipid, ethanol and water [3]. Although the preparation method that these authors describe is different from that used in our systems, both structures could be similar. Our results seem to indicate an spontaneous inversion of the lipids of the outer monolayer of the liposomes depending on the polarity of the medium. This strategy might be considered as an adaptation of the liposomes to explain their pass through the lipid regions of the SC. This adaptation is based on two points: vesicles become more flexible and their outer surface becomes more lipophilic. Thus, the formation of "inverted liposomes" with a higher affinity for the lipid environment of the SC and, therefore, with more probability to cross this potent barrier could be of great interest in the development of new topical preparations.

CONCLUSIONS

- ☆ Phospholipid liposomes show certain molecular mobility depending on the polarity of the medium. This fact would constitute a strategy of adaptation to explain the pass of the liposomes through the lipid regions of the SC which have a specific polarity.
- ☆ This molecular mobility due to the ethanol could induce the formation of liposomes where the lipids of the outer bilayer are inverted: "inverted liposomes".
- ☆ This kind of liposomes in media of certain polarity (less than 30% ethanol) are vesicles relatively stable. Thus, with more probability to cross this potent barrier could be of great interest in the development of new topical preparations.

REFERENCES

- López, O. de la Maza, A., Coderch, L., López-Iglesias, C., Wehrli, E. and Parrs, J.L. (1998) *FEBS Lett.* 426: 314-318.
- Parellón, J., Martí, M., de la Maza, A., Sebás, M., Parrs, J.L. and Coderch, L. (2000) *Langmuir* 16(11):4606-4612.
- Touitou, E., Doyan, N., Bergelson, L., Gada, B. and Eliaz, M. (2000) *J. Control. Rel.* 65: 403-418.

Do you have any question, suggestion, comment? olopez@cid.csic.es